Review



apc anti human cd3  (Elabscience Biotechnology)


Bioz Verified Symbol Elabscience Biotechnology is a verified supplier
Bioz Manufacturer Symbol Elabscience Biotechnology manufactures this product  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
  • 93

    Structured Review

    Elabscience Biotechnology apc anti human cd3
    a Body weight of mice with intravenous treatments during a 28-day period ( n = 5 independent mice). b The blood analysis for the liver/kidney functions including ALT, AST, BUN, and CRE was determined on day 28 following the treatments ( n = 5 independent mice). c The curve of injected drug concentration (ID %) versus time point was plotted in subcutaneous HCC mice ( n = 6 independent mice). d Fluorescence imaging of the biodistribution in orthotopic HCC mice at 12 h after different treatments (tumors marked with yellow circles; n = 6 independent mice). e Tumor-to-background ratio for different treatments in ( d ) ( n = 6 independent mice). f Quantitative biodistribution analysis of DiR-labeled nanoparticles in major organs and liver tumors in ( d ) ( n = 6 independent mice). g Fluorescence images of Sv@PM-M2p inside HCC cells, M2 TAMs, M1 TAMs, DCs, and T cells in tumors ( n = 6 independent mice; Scale bar = 100 μm). Sv@PM-M2p was labeled with Rhodamine (red), the nuclei and cell markers (HCC, CK8; M2, CD206; M1, CD86; DC, CD11c; T, <t>CD3)</t> were stained with DAPI (blue) and antibody (green), respectively. h Quantification of the percentage of colocated cells in ( g ) ( n = 6 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , e , f , h ) and P -values were indicated. Source data are provided as a Source Data file.
    Apc Anti Human Cd3, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 5 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apc anti human cd3/product/Elabscience Biotechnology
    Average 93 stars, based on 5 article reviews
    apc anti human cd3 - by Bioz Stars, 2026-05
    93/100 stars

    Images

    1) Product Images from "Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma"

    Article Title: Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma

    Journal: Nature Communications

    doi: 10.1038/s41467-025-65056-9

    a Body weight of mice with intravenous treatments during a 28-day period ( n = 5 independent mice). b The blood analysis for the liver/kidney functions including ALT, AST, BUN, and CRE was determined on day 28 following the treatments ( n = 5 independent mice). c The curve of injected drug concentration (ID %) versus time point was plotted in subcutaneous HCC mice ( n = 6 independent mice). d Fluorescence imaging of the biodistribution in orthotopic HCC mice at 12 h after different treatments (tumors marked with yellow circles; n = 6 independent mice). e Tumor-to-background ratio for different treatments in ( d ) ( n = 6 independent mice). f Quantitative biodistribution analysis of DiR-labeled nanoparticles in major organs and liver tumors in ( d ) ( n = 6 independent mice). g Fluorescence images of Sv@PM-M2p inside HCC cells, M2 TAMs, M1 TAMs, DCs, and T cells in tumors ( n = 6 independent mice; Scale bar = 100 μm). Sv@PM-M2p was labeled with Rhodamine (red), the nuclei and cell markers (HCC, CK8; M2, CD206; M1, CD86; DC, CD11c; T, CD3) were stained with DAPI (blue) and antibody (green), respectively. h Quantification of the percentage of colocated cells in ( g ) ( n = 6 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , e , f , h ) and P -values were indicated. Source data are provided as a Source Data file.
    Figure Legend Snippet: a Body weight of mice with intravenous treatments during a 28-day period ( n = 5 independent mice). b The blood analysis for the liver/kidney functions including ALT, AST, BUN, and CRE was determined on day 28 following the treatments ( n = 5 independent mice). c The curve of injected drug concentration (ID %) versus time point was plotted in subcutaneous HCC mice ( n = 6 independent mice). d Fluorescence imaging of the biodistribution in orthotopic HCC mice at 12 h after different treatments (tumors marked with yellow circles; n = 6 independent mice). e Tumor-to-background ratio for different treatments in ( d ) ( n = 6 independent mice). f Quantitative biodistribution analysis of DiR-labeled nanoparticles in major organs and liver tumors in ( d ) ( n = 6 independent mice). g Fluorescence images of Sv@PM-M2p inside HCC cells, M2 TAMs, M1 TAMs, DCs, and T cells in tumors ( n = 6 independent mice; Scale bar = 100 μm). Sv@PM-M2p was labeled with Rhodamine (red), the nuclei and cell markers (HCC, CK8; M2, CD206; M1, CD86; DC, CD11c; T, CD3) were stained with DAPI (blue) and antibody (green), respectively. h Quantification of the percentage of colocated cells in ( g ) ( n = 6 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , e , f , h ) and P -values were indicated. Source data are provided as a Source Data file.

    Techniques Used: Injection, Concentration Assay, Fluorescence, Imaging, Labeling, Staining

    a Schematic illustration of the research procedure in subcutaneous HCC mouse model. b Relative tumor volume curves of different treatment groups ( n = 5 independent mice). c Animal survival after different treatments ( n = 5 independent mice). d Quantification of fluorescence intensity in Supplementary Fig. f ( n = 5 independent mice). e Immunofluorescence images of tumor tissue slices collected from different groups stained with anti-F4/80/CD206, anti-F4/80/CD86, and anti-CD11c/MHC II after different treatments ( n = 5 independent mice; Scale bar = 100 μm). f Quantification of the percentage of F4/80 + CD206 + M2 TAMs, F4/80 + CD86 + M1 TAMs, and CD11c + MHC II + actDCs in ( e ) ( n = 5 independent mice). g Schematic illustration of the research procedure in orthotopic HCC mouse model. h Relative bioluminescence intensity curves for the various treatment groups ( n = 5 independent mice). i Animal survival after different treatments ( n = 5 independent mice). j Flow cytometric analysis of anti-F4/80/CD206-stained macrophages, anti-F4/80/CD86-stained macrophages, anti-CD11c/MHC II-stained DCs, anti-CD3/CD4-stained T cells, anti-CD3/CD8-stained T cells, and anti-CD4/Foxp3-stained T cells in tumor tissues after different treatments ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , d , f , h ) or log-rank test ( c , i ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 7a, g were created by Adobe Illustrator.
    Figure Legend Snippet: a Schematic illustration of the research procedure in subcutaneous HCC mouse model. b Relative tumor volume curves of different treatment groups ( n = 5 independent mice). c Animal survival after different treatments ( n = 5 independent mice). d Quantification of fluorescence intensity in Supplementary Fig. f ( n = 5 independent mice). e Immunofluorescence images of tumor tissue slices collected from different groups stained with anti-F4/80/CD206, anti-F4/80/CD86, and anti-CD11c/MHC II after different treatments ( n = 5 independent mice; Scale bar = 100 μm). f Quantification of the percentage of F4/80 + CD206 + M2 TAMs, F4/80 + CD86 + M1 TAMs, and CD11c + MHC II + actDCs in ( e ) ( n = 5 independent mice). g Schematic illustration of the research procedure in orthotopic HCC mouse model. h Relative bioluminescence intensity curves for the various treatment groups ( n = 5 independent mice). i Animal survival after different treatments ( n = 5 independent mice). j Flow cytometric analysis of anti-F4/80/CD206-stained macrophages, anti-F4/80/CD86-stained macrophages, anti-CD11c/MHC II-stained DCs, anti-CD3/CD4-stained T cells, anti-CD3/CD8-stained T cells, and anti-CD4/Foxp3-stained T cells in tumor tissues after different treatments ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , d , f , h ) or log-rank test ( c , i ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 7a, g were created by Adobe Illustrator.

    Techniques Used: Fluorescence, Immunofluorescence, Staining

    a Flow cytometric analysis of anti-PD-L1-stained cells in tumor tissues after different treatments ( n = 5 independent mice). b Quantification of the percentage of PD-L1 positive cells in ( a ) ( n = 5 independent mice). c Schematic diagram of the mechanism of Sv@PM-M2p-mediated upregulation of PD-L1 within HCC TME. d Schematic illustration of the research procedure in bilateral subcutaneous HCC mouse model. e Representative bioluminescence images of bilateral subcutaneous HCC mice at specific time points with different treatments ( n = 5 independent mice). f Relative bioluminescence intensity curves for the various treatment groups ( n = 5 independent mice). g Flow cytometric analysis of anti-F4/80/CD206-stained macrophages and anti-F4/80/CD86-stained macrophages in tumor tissues after different treatments ( n = 5 independent mice). h Quantification of the percentage of F4/80 + CD206 + M2 TAMs and F4/80 + CD86 + M1 TAMs in ( g ) ( n = 5 independent mice). i Flow cytometric analysis of anti-CD44/CD62L-stained T cells (gated on CD3 + CD8 + T cells) in the spleens after different treatments ( n = 5 independent mice). j Quantification of the percentage of CD44 + CD62L - memory T cells in ( i ) ( n = 5 independent mice). k The assay of IFN-γ, TNF, IL-6, and IL-12 in serum after different treatments ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , f , h , j , k ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 8c, d were created by Adobe Illustrator.
    Figure Legend Snippet: a Flow cytometric analysis of anti-PD-L1-stained cells in tumor tissues after different treatments ( n = 5 independent mice). b Quantification of the percentage of PD-L1 positive cells in ( a ) ( n = 5 independent mice). c Schematic diagram of the mechanism of Sv@PM-M2p-mediated upregulation of PD-L1 within HCC TME. d Schematic illustration of the research procedure in bilateral subcutaneous HCC mouse model. e Representative bioluminescence images of bilateral subcutaneous HCC mice at specific time points with different treatments ( n = 5 independent mice). f Relative bioluminescence intensity curves for the various treatment groups ( n = 5 independent mice). g Flow cytometric analysis of anti-F4/80/CD206-stained macrophages and anti-F4/80/CD86-stained macrophages in tumor tissues after different treatments ( n = 5 independent mice). h Quantification of the percentage of F4/80 + CD206 + M2 TAMs and F4/80 + CD86 + M1 TAMs in ( g ) ( n = 5 independent mice). i Flow cytometric analysis of anti-CD44/CD62L-stained T cells (gated on CD3 + CD8 + T cells) in the spleens after different treatments ( n = 5 independent mice). j Quantification of the percentage of CD44 + CD62L - memory T cells in ( i ) ( n = 5 independent mice). k The assay of IFN-γ, TNF, IL-6, and IL-12 in serum after different treatments ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , f , h , j , k ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 8c, d were created by Adobe Illustrator.

    Techniques Used: Staining

    a Schematic illustration of the research procedure in PDX subcutaneous mouse model. b Relative tumor volume curves of different treatment groups ( n = 5 independent mice). c Collected tumor tissues of mice at the end of treatment in different groups. d Tumor weight at the end of treatment in different groups ( n = 5 independent mice). e Immunofluorescence images of tumor tissue slices collected from different groups stained with Liperfluo after different treatments ( n = 5 independent mice; Scale bar = 100 μm). f Quantification of fluorescence intensity in ( e ) ( n = 5 independent mice). g Flow cytometric analysis of anti-CD68/CD206-stained macrophages (gated on CD45 + cells), anti-CD68/CD80-stained macrophages (gated on CD45 + cells), anti-HLA-DR/CD11c-stained DCs (gated on CD45 + Lin-1 – T cells), and anti-CD3/CD8-stained T cells (gated on CD45 + cells) in tumor tissues after different treatments ( n = 5 independent mice). h Quantification of the percentage of CD68 + CD206 + M2 TAMs, CD68 + CD80 + M1 TAMs, HLA-DR + CD11c + actDCs, and CD3 + CD8 + Tc cells in ( g ) ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , d , f , h ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 9a were created by Adobe Illustrator.
    Figure Legend Snippet: a Schematic illustration of the research procedure in PDX subcutaneous mouse model. b Relative tumor volume curves of different treatment groups ( n = 5 independent mice). c Collected tumor tissues of mice at the end of treatment in different groups. d Tumor weight at the end of treatment in different groups ( n = 5 independent mice). e Immunofluorescence images of tumor tissue slices collected from different groups stained with Liperfluo after different treatments ( n = 5 independent mice; Scale bar = 100 μm). f Quantification of fluorescence intensity in ( e ) ( n = 5 independent mice). g Flow cytometric analysis of anti-CD68/CD206-stained macrophages (gated on CD45 + cells), anti-CD68/CD80-stained macrophages (gated on CD45 + cells), anti-HLA-DR/CD11c-stained DCs (gated on CD45 + Lin-1 – T cells), and anti-CD3/CD8-stained T cells (gated on CD45 + cells) in tumor tissues after different treatments ( n = 5 independent mice). h Quantification of the percentage of CD68 + CD206 + M2 TAMs, CD68 + CD80 + M1 TAMs, HLA-DR + CD11c + actDCs, and CD3 + CD8 + Tc cells in ( g ) ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , d , f , h ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 9a were created by Adobe Illustrator.

    Techniques Used: Immunofluorescence, Staining, Fluorescence



    Similar Products

    93
    Elabscience Biotechnology apc anti human cd3
    a Body weight of mice with intravenous treatments during a 28-day period ( n = 5 independent mice). b The blood analysis for the liver/kidney functions including ALT, AST, BUN, and CRE was determined on day 28 following the treatments ( n = 5 independent mice). c The curve of injected drug concentration (ID %) versus time point was plotted in subcutaneous HCC mice ( n = 6 independent mice). d Fluorescence imaging of the biodistribution in orthotopic HCC mice at 12 h after different treatments (tumors marked with yellow circles; n = 6 independent mice). e Tumor-to-background ratio for different treatments in ( d ) ( n = 6 independent mice). f Quantitative biodistribution analysis of DiR-labeled nanoparticles in major organs and liver tumors in ( d ) ( n = 6 independent mice). g Fluorescence images of Sv@PM-M2p inside HCC cells, M2 TAMs, M1 TAMs, DCs, and T cells in tumors ( n = 6 independent mice; Scale bar = 100 μm). Sv@PM-M2p was labeled with Rhodamine (red), the nuclei and cell markers (HCC, CK8; M2, CD206; M1, CD86; DC, CD11c; T, <t>CD3)</t> were stained with DAPI (blue) and antibody (green), respectively. h Quantification of the percentage of colocated cells in ( g ) ( n = 6 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , e , f , h ) and P -values were indicated. Source data are provided as a Source Data file.
    Apc Anti Human Cd3, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apc anti human cd3/product/Elabscience Biotechnology
    Average 93 stars, based on 1 article reviews
    apc anti human cd3 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    Elabscience Biotechnology apc anti human cd3 antibody
    a Body weight of mice with intravenous treatments during a 28-day period ( n = 5 independent mice). b The blood analysis for the liver/kidney functions including ALT, AST, BUN, and CRE was determined on day 28 following the treatments ( n = 5 independent mice). c The curve of injected drug concentration (ID %) versus time point was plotted in subcutaneous HCC mice ( n = 6 independent mice). d Fluorescence imaging of the biodistribution in orthotopic HCC mice at 12 h after different treatments (tumors marked with yellow circles; n = 6 independent mice). e Tumor-to-background ratio for different treatments in ( d ) ( n = 6 independent mice). f Quantitative biodistribution analysis of DiR-labeled nanoparticles in major organs and liver tumors in ( d ) ( n = 6 independent mice). g Fluorescence images of Sv@PM-M2p inside HCC cells, M2 TAMs, M1 TAMs, DCs, and T cells in tumors ( n = 6 independent mice; Scale bar = 100 μm). Sv@PM-M2p was labeled with Rhodamine (red), the nuclei and cell markers (HCC, CK8; M2, CD206; M1, CD86; DC, CD11c; T, <t>CD3)</t> were stained with DAPI (blue) and antibody (green), respectively. h Quantification of the percentage of colocated cells in ( g ) ( n = 6 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , e , f , h ) and P -values were indicated. Source data are provided as a Source Data file.
    Apc Anti Human Cd3 Antibody, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apc anti human cd3 antibody/product/Elabscience Biotechnology
    Average 93 stars, based on 1 article reviews
    apc anti human cd3 antibody - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    Elabscience Biotechnology cd3
    a Body weight of mice with intravenous treatments during a 28-day period ( n = 5 independent mice). b The blood analysis for the liver/kidney functions including ALT, AST, BUN, and CRE was determined on day 28 following the treatments ( n = 5 independent mice). c The curve of injected drug concentration (ID %) versus time point was plotted in subcutaneous HCC mice ( n = 6 independent mice). d Fluorescence imaging of the biodistribution in orthotopic HCC mice at 12 h after different treatments (tumors marked with yellow circles; n = 6 independent mice). e Tumor-to-background ratio for different treatments in ( d ) ( n = 6 independent mice). f Quantitative biodistribution analysis of DiR-labeled nanoparticles in major organs and liver tumors in ( d ) ( n = 6 independent mice). g Fluorescence images of Sv@PM-M2p inside HCC cells, M2 TAMs, M1 TAMs, DCs, and T cells in tumors ( n = 6 independent mice; Scale bar = 100 μm). Sv@PM-M2p was labeled with Rhodamine (red), the nuclei and cell markers (HCC, CK8; M2, CD206; M1, CD86; DC, CD11c; T, <t>CD3)</t> were stained with DAPI (blue) and antibody (green), respectively. h Quantification of the percentage of colocated cells in ( g ) ( n = 6 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , e , f , h ) and P -values were indicated. Source data are provided as a Source Data file.
    Cd3, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cd3/product/Elabscience Biotechnology
    Average 93 stars, based on 1 article reviews
    cd3 - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    Elabscience Biotechnology apcanti human cd3 antibody
    a Body weight of mice with intravenous treatments during a 28-day period ( n = 5 independent mice). b The blood analysis for the liver/kidney functions including ALT, AST, BUN, and CRE was determined on day 28 following the treatments ( n = 5 independent mice). c The curve of injected drug concentration (ID %) versus time point was plotted in subcutaneous HCC mice ( n = 6 independent mice). d Fluorescence imaging of the biodistribution in orthotopic HCC mice at 12 h after different treatments (tumors marked with yellow circles; n = 6 independent mice). e Tumor-to-background ratio for different treatments in ( d ) ( n = 6 independent mice). f Quantitative biodistribution analysis of DiR-labeled nanoparticles in major organs and liver tumors in ( d ) ( n = 6 independent mice). g Fluorescence images of Sv@PM-M2p inside HCC cells, M2 TAMs, M1 TAMs, DCs, and T cells in tumors ( n = 6 independent mice; Scale bar = 100 μm). Sv@PM-M2p was labeled with Rhodamine (red), the nuclei and cell markers (HCC, CK8; M2, CD206; M1, CD86; DC, CD11c; T, <t>CD3)</t> were stained with DAPI (blue) and antibody (green), respectively. h Quantification of the percentage of colocated cells in ( g ) ( n = 6 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , e , f , h ) and P -values were indicated. Source data are provided as a Source Data file.
    Apcanti Human Cd3 Antibody, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/apcanti human cd3 antibody/product/Elabscience Biotechnology
    Average 93 stars, based on 1 article reviews
    apcanti human cd3 antibody - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    93
    Elabscience Biotechnology e ab f1001e
    The information of antibodies used for western blot, immunohistochemistry, and flow cytometry
    E Ab F1001e, supplied by Elabscience Biotechnology, used in various techniques. Bioz Stars score: 93/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/e ab f1001e/product/Elabscience Biotechnology
    Average 93 stars, based on 1 article reviews
    e ab f1001e - by Bioz Stars, 2026-05
    93/100 stars
      Buy from Supplier

    Image Search Results


    a Body weight of mice with intravenous treatments during a 28-day period ( n = 5 independent mice). b The blood analysis for the liver/kidney functions including ALT, AST, BUN, and CRE was determined on day 28 following the treatments ( n = 5 independent mice). c The curve of injected drug concentration (ID %) versus time point was plotted in subcutaneous HCC mice ( n = 6 independent mice). d Fluorescence imaging of the biodistribution in orthotopic HCC mice at 12 h after different treatments (tumors marked with yellow circles; n = 6 independent mice). e Tumor-to-background ratio for different treatments in ( d ) ( n = 6 independent mice). f Quantitative biodistribution analysis of DiR-labeled nanoparticles in major organs and liver tumors in ( d ) ( n = 6 independent mice). g Fluorescence images of Sv@PM-M2p inside HCC cells, M2 TAMs, M1 TAMs, DCs, and T cells in tumors ( n = 6 independent mice; Scale bar = 100 μm). Sv@PM-M2p was labeled with Rhodamine (red), the nuclei and cell markers (HCC, CK8; M2, CD206; M1, CD86; DC, CD11c; T, CD3) were stained with DAPI (blue) and antibody (green), respectively. h Quantification of the percentage of colocated cells in ( g ) ( n = 6 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , e , f , h ) and P -values were indicated. Source data are provided as a Source Data file.

    Journal: Nature Communications

    Article Title: Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma

    doi: 10.1038/s41467-025-65056-9

    Figure Lengend Snippet: a Body weight of mice with intravenous treatments during a 28-day period ( n = 5 independent mice). b The blood analysis for the liver/kidney functions including ALT, AST, BUN, and CRE was determined on day 28 following the treatments ( n = 5 independent mice). c The curve of injected drug concentration (ID %) versus time point was plotted in subcutaneous HCC mice ( n = 6 independent mice). d Fluorescence imaging of the biodistribution in orthotopic HCC mice at 12 h after different treatments (tumors marked with yellow circles; n = 6 independent mice). e Tumor-to-background ratio for different treatments in ( d ) ( n = 6 independent mice). f Quantitative biodistribution analysis of DiR-labeled nanoparticles in major organs and liver tumors in ( d ) ( n = 6 independent mice). g Fluorescence images of Sv@PM-M2p inside HCC cells, M2 TAMs, M1 TAMs, DCs, and T cells in tumors ( n = 6 independent mice; Scale bar = 100 μm). Sv@PM-M2p was labeled with Rhodamine (red), the nuclei and cell markers (HCC, CK8; M2, CD206; M1, CD86; DC, CD11c; T, CD3) were stained with DAPI (blue) and antibody (green), respectively. h Quantification of the percentage of colocated cells in ( g ) ( n = 6 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( c , e , f , h ) and P -values were indicated. Source data are provided as a Source Data file.

    Article Snippet: PerCP/Cyanine5.5 anti-mouse F4/80 (1:200, #E-AB-F0995J), APC anti-mouse CD206 (1:200, #E-AB-F1135E), PE/Cyanine7 anti-mouse CD86 (1:200, #E-AB-F0994H), Fluor Red 780 anti-mouse CD80 (1:200, #E-AB-F0992S), APC anti-mouse CD11c (1:200, #E-AB-F0991E), Fluor Violet 450 anti-mouse CD3 (1:200, #E-AB-F1013Q), Fluor Red 780 anti-mouse CD4 (1:200, #E-AB-F1097S), PerCP/Cyanine5.5 anti-mouse CD8 (1:200, #E-AB-F1104J), FITC anti-human/mouse CD44 (1:200, #E-AB-F1100C), PE anti-mouse Foxp3 (1:200, #E-AB-F1238D), FITC anti-mouse MHC II (1:200, #E-AB-F0990C), APC anti-mouse CD62L (1:200, #E-AB-F1011E), APC anti-mouse PD-L1 (1:200, #E-AB-F1132E), PerCP anti-human CD45 (1:200, #E-AB-F1137F), Fluor647 anti-human CD68 (1:200, #E-AB-F1299M), FITC anti-human CD206 (1:200, #E-AB-F1161C), PE anti-human CD80 (1:200, #E-AB-F1232D), APC anti-human HLA-DR (1:200, #E-AB-F1111E), PE anti-human CD11c (1:200, #E-AB-F1118D), APC anti-human CD3 (1:200, #E-AB-F1001E), and FITC anti-human CD8 (1:200, #E-AB-F1110C) were purchased from Elabscience (Wuhan, China).

    Techniques: Injection, Concentration Assay, Fluorescence, Imaging, Labeling, Staining

    a Schematic illustration of the research procedure in subcutaneous HCC mouse model. b Relative tumor volume curves of different treatment groups ( n = 5 independent mice). c Animal survival after different treatments ( n = 5 independent mice). d Quantification of fluorescence intensity in Supplementary Fig. f ( n = 5 independent mice). e Immunofluorescence images of tumor tissue slices collected from different groups stained with anti-F4/80/CD206, anti-F4/80/CD86, and anti-CD11c/MHC II after different treatments ( n = 5 independent mice; Scale bar = 100 μm). f Quantification of the percentage of F4/80 + CD206 + M2 TAMs, F4/80 + CD86 + M1 TAMs, and CD11c + MHC II + actDCs in ( e ) ( n = 5 independent mice). g Schematic illustration of the research procedure in orthotopic HCC mouse model. h Relative bioluminescence intensity curves for the various treatment groups ( n = 5 independent mice). i Animal survival after different treatments ( n = 5 independent mice). j Flow cytometric analysis of anti-F4/80/CD206-stained macrophages, anti-F4/80/CD86-stained macrophages, anti-CD11c/MHC II-stained DCs, anti-CD3/CD4-stained T cells, anti-CD3/CD8-stained T cells, and anti-CD4/Foxp3-stained T cells in tumor tissues after different treatments ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , d , f , h ) or log-rank test ( c , i ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 7a, g were created by Adobe Illustrator.

    Journal: Nature Communications

    Article Title: Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma

    doi: 10.1038/s41467-025-65056-9

    Figure Lengend Snippet: a Schematic illustration of the research procedure in subcutaneous HCC mouse model. b Relative tumor volume curves of different treatment groups ( n = 5 independent mice). c Animal survival after different treatments ( n = 5 independent mice). d Quantification of fluorescence intensity in Supplementary Fig. f ( n = 5 independent mice). e Immunofluorescence images of tumor tissue slices collected from different groups stained with anti-F4/80/CD206, anti-F4/80/CD86, and anti-CD11c/MHC II after different treatments ( n = 5 independent mice; Scale bar = 100 μm). f Quantification of the percentage of F4/80 + CD206 + M2 TAMs, F4/80 + CD86 + M1 TAMs, and CD11c + MHC II + actDCs in ( e ) ( n = 5 independent mice). g Schematic illustration of the research procedure in orthotopic HCC mouse model. h Relative bioluminescence intensity curves for the various treatment groups ( n = 5 independent mice). i Animal survival after different treatments ( n = 5 independent mice). j Flow cytometric analysis of anti-F4/80/CD206-stained macrophages, anti-F4/80/CD86-stained macrophages, anti-CD11c/MHC II-stained DCs, anti-CD3/CD4-stained T cells, anti-CD3/CD8-stained T cells, and anti-CD4/Foxp3-stained T cells in tumor tissues after different treatments ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , d , f , h ) or log-rank test ( c , i ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 7a, g were created by Adobe Illustrator.

    Article Snippet: PerCP/Cyanine5.5 anti-mouse F4/80 (1:200, #E-AB-F0995J), APC anti-mouse CD206 (1:200, #E-AB-F1135E), PE/Cyanine7 anti-mouse CD86 (1:200, #E-AB-F0994H), Fluor Red 780 anti-mouse CD80 (1:200, #E-AB-F0992S), APC anti-mouse CD11c (1:200, #E-AB-F0991E), Fluor Violet 450 anti-mouse CD3 (1:200, #E-AB-F1013Q), Fluor Red 780 anti-mouse CD4 (1:200, #E-AB-F1097S), PerCP/Cyanine5.5 anti-mouse CD8 (1:200, #E-AB-F1104J), FITC anti-human/mouse CD44 (1:200, #E-AB-F1100C), PE anti-mouse Foxp3 (1:200, #E-AB-F1238D), FITC anti-mouse MHC II (1:200, #E-AB-F0990C), APC anti-mouse CD62L (1:200, #E-AB-F1011E), APC anti-mouse PD-L1 (1:200, #E-AB-F1132E), PerCP anti-human CD45 (1:200, #E-AB-F1137F), Fluor647 anti-human CD68 (1:200, #E-AB-F1299M), FITC anti-human CD206 (1:200, #E-AB-F1161C), PE anti-human CD80 (1:200, #E-AB-F1232D), APC anti-human HLA-DR (1:200, #E-AB-F1111E), PE anti-human CD11c (1:200, #E-AB-F1118D), APC anti-human CD3 (1:200, #E-AB-F1001E), and FITC anti-human CD8 (1:200, #E-AB-F1110C) were purchased from Elabscience (Wuhan, China).

    Techniques: Fluorescence, Immunofluorescence, Staining

    a Flow cytometric analysis of anti-PD-L1-stained cells in tumor tissues after different treatments ( n = 5 independent mice). b Quantification of the percentage of PD-L1 positive cells in ( a ) ( n = 5 independent mice). c Schematic diagram of the mechanism of Sv@PM-M2p-mediated upregulation of PD-L1 within HCC TME. d Schematic illustration of the research procedure in bilateral subcutaneous HCC mouse model. e Representative bioluminescence images of bilateral subcutaneous HCC mice at specific time points with different treatments ( n = 5 independent mice). f Relative bioluminescence intensity curves for the various treatment groups ( n = 5 independent mice). g Flow cytometric analysis of anti-F4/80/CD206-stained macrophages and anti-F4/80/CD86-stained macrophages in tumor tissues after different treatments ( n = 5 independent mice). h Quantification of the percentage of F4/80 + CD206 + M2 TAMs and F4/80 + CD86 + M1 TAMs in ( g ) ( n = 5 independent mice). i Flow cytometric analysis of anti-CD44/CD62L-stained T cells (gated on CD3 + CD8 + T cells) in the spleens after different treatments ( n = 5 independent mice). j Quantification of the percentage of CD44 + CD62L - memory T cells in ( i ) ( n = 5 independent mice). k The assay of IFN-γ, TNF, IL-6, and IL-12 in serum after different treatments ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , f , h , j , k ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 8c, d were created by Adobe Illustrator.

    Journal: Nature Communications

    Article Title: Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma

    doi: 10.1038/s41467-025-65056-9

    Figure Lengend Snippet: a Flow cytometric analysis of anti-PD-L1-stained cells in tumor tissues after different treatments ( n = 5 independent mice). b Quantification of the percentage of PD-L1 positive cells in ( a ) ( n = 5 independent mice). c Schematic diagram of the mechanism of Sv@PM-M2p-mediated upregulation of PD-L1 within HCC TME. d Schematic illustration of the research procedure in bilateral subcutaneous HCC mouse model. e Representative bioluminescence images of bilateral subcutaneous HCC mice at specific time points with different treatments ( n = 5 independent mice). f Relative bioluminescence intensity curves for the various treatment groups ( n = 5 independent mice). g Flow cytometric analysis of anti-F4/80/CD206-stained macrophages and anti-F4/80/CD86-stained macrophages in tumor tissues after different treatments ( n = 5 independent mice). h Quantification of the percentage of F4/80 + CD206 + M2 TAMs and F4/80 + CD86 + M1 TAMs in ( g ) ( n = 5 independent mice). i Flow cytometric analysis of anti-CD44/CD62L-stained T cells (gated on CD3 + CD8 + T cells) in the spleens after different treatments ( n = 5 independent mice). j Quantification of the percentage of CD44 + CD62L - memory T cells in ( i ) ( n = 5 independent mice). k The assay of IFN-γ, TNF, IL-6, and IL-12 in serum after different treatments ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , f , h , j , k ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 8c, d were created by Adobe Illustrator.

    Article Snippet: PerCP/Cyanine5.5 anti-mouse F4/80 (1:200, #E-AB-F0995J), APC anti-mouse CD206 (1:200, #E-AB-F1135E), PE/Cyanine7 anti-mouse CD86 (1:200, #E-AB-F0994H), Fluor Red 780 anti-mouse CD80 (1:200, #E-AB-F0992S), APC anti-mouse CD11c (1:200, #E-AB-F0991E), Fluor Violet 450 anti-mouse CD3 (1:200, #E-AB-F1013Q), Fluor Red 780 anti-mouse CD4 (1:200, #E-AB-F1097S), PerCP/Cyanine5.5 anti-mouse CD8 (1:200, #E-AB-F1104J), FITC anti-human/mouse CD44 (1:200, #E-AB-F1100C), PE anti-mouse Foxp3 (1:200, #E-AB-F1238D), FITC anti-mouse MHC II (1:200, #E-AB-F0990C), APC anti-mouse CD62L (1:200, #E-AB-F1011E), APC anti-mouse PD-L1 (1:200, #E-AB-F1132E), PerCP anti-human CD45 (1:200, #E-AB-F1137F), Fluor647 anti-human CD68 (1:200, #E-AB-F1299M), FITC anti-human CD206 (1:200, #E-AB-F1161C), PE anti-human CD80 (1:200, #E-AB-F1232D), APC anti-human HLA-DR (1:200, #E-AB-F1111E), PE anti-human CD11c (1:200, #E-AB-F1118D), APC anti-human CD3 (1:200, #E-AB-F1001E), and FITC anti-human CD8 (1:200, #E-AB-F1110C) were purchased from Elabscience (Wuhan, China).

    Techniques: Staining

    a Schematic illustration of the research procedure in PDX subcutaneous mouse model. b Relative tumor volume curves of different treatment groups ( n = 5 independent mice). c Collected tumor tissues of mice at the end of treatment in different groups. d Tumor weight at the end of treatment in different groups ( n = 5 independent mice). e Immunofluorescence images of tumor tissue slices collected from different groups stained with Liperfluo after different treatments ( n = 5 independent mice; Scale bar = 100 μm). f Quantification of fluorescence intensity in ( e ) ( n = 5 independent mice). g Flow cytometric analysis of anti-CD68/CD206-stained macrophages (gated on CD45 + cells), anti-CD68/CD80-stained macrophages (gated on CD45 + cells), anti-HLA-DR/CD11c-stained DCs (gated on CD45 + Lin-1 – T cells), and anti-CD3/CD8-stained T cells (gated on CD45 + cells) in tumor tissues after different treatments ( n = 5 independent mice). h Quantification of the percentage of CD68 + CD206 + M2 TAMs, CD68 + CD80 + M1 TAMs, HLA-DR + CD11c + actDCs, and CD3 + CD8 + Tc cells in ( g ) ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , d , f , h ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 9a were created by Adobe Illustrator.

    Journal: Nature Communications

    Article Title: Co-delivery of sorafenib and an FSP1 inhibitor triggers dual ferroptosis in tumor cells and immunosuppressive macrophages for enhanced immunotherapy in mouse models of hepatocellular carcinoma

    doi: 10.1038/s41467-025-65056-9

    Figure Lengend Snippet: a Schematic illustration of the research procedure in PDX subcutaneous mouse model. b Relative tumor volume curves of different treatment groups ( n = 5 independent mice). c Collected tumor tissues of mice at the end of treatment in different groups. d Tumor weight at the end of treatment in different groups ( n = 5 independent mice). e Immunofluorescence images of tumor tissue slices collected from different groups stained with Liperfluo after different treatments ( n = 5 independent mice; Scale bar = 100 μm). f Quantification of fluorescence intensity in ( e ) ( n = 5 independent mice). g Flow cytometric analysis of anti-CD68/CD206-stained macrophages (gated on CD45 + cells), anti-CD68/CD80-stained macrophages (gated on CD45 + cells), anti-HLA-DR/CD11c-stained DCs (gated on CD45 + Lin-1 – T cells), and anti-CD3/CD8-stained T cells (gated on CD45 + cells) in tumor tissues after different treatments ( n = 5 independent mice). h Quantification of the percentage of CD68 + CD206 + M2 TAMs, CD68 + CD80 + M1 TAMs, HLA-DR + CD11c + actDCs, and CD3 + CD8 + Tc cells in ( g ) ( n = 5 independent mice). Unless specified otherwise, error bars represent the mean ± SEM. Statistical significance was determined by one-way ANOVA with Tukey’s test ( b , d , f , h ) and P -values were indicated. Source data are provided as a Source Data file. The elements in Fig. 9a were created by Adobe Illustrator.

    Article Snippet: PerCP/Cyanine5.5 anti-mouse F4/80 (1:200, #E-AB-F0995J), APC anti-mouse CD206 (1:200, #E-AB-F1135E), PE/Cyanine7 anti-mouse CD86 (1:200, #E-AB-F0994H), Fluor Red 780 anti-mouse CD80 (1:200, #E-AB-F0992S), APC anti-mouse CD11c (1:200, #E-AB-F0991E), Fluor Violet 450 anti-mouse CD3 (1:200, #E-AB-F1013Q), Fluor Red 780 anti-mouse CD4 (1:200, #E-AB-F1097S), PerCP/Cyanine5.5 anti-mouse CD8 (1:200, #E-AB-F1104J), FITC anti-human/mouse CD44 (1:200, #E-AB-F1100C), PE anti-mouse Foxp3 (1:200, #E-AB-F1238D), FITC anti-mouse MHC II (1:200, #E-AB-F0990C), APC anti-mouse CD62L (1:200, #E-AB-F1011E), APC anti-mouse PD-L1 (1:200, #E-AB-F1132E), PerCP anti-human CD45 (1:200, #E-AB-F1137F), Fluor647 anti-human CD68 (1:200, #E-AB-F1299M), FITC anti-human CD206 (1:200, #E-AB-F1161C), PE anti-human CD80 (1:200, #E-AB-F1232D), APC anti-human HLA-DR (1:200, #E-AB-F1111E), PE anti-human CD11c (1:200, #E-AB-F1118D), APC anti-human CD3 (1:200, #E-AB-F1001E), and FITC anti-human CD8 (1:200, #E-AB-F1110C) were purchased from Elabscience (Wuhan, China).

    Techniques: Immunofluorescence, Staining, Fluorescence

    The information of antibodies used for western blot, immunohistochemistry, and flow cytometry

    Journal: Journal of Translational Medicine

    Article Title: Niraparib exhibits a synergistic anti-tumor effect with PD-L1 blockade by inducing an immune response in ovarian cancer

    doi: 10.1186/s12967-021-03073-0

    Figure Lengend Snippet: The information of antibodies used for western blot, immunohistochemistry, and flow cytometry

    Article Snippet: CD3 and isotype , Human , 5 μl of antibody per test , Elabscience, E-AB-F1001E , Flow cytometry.

    Techniques: Western Blot, Immunohistochemistry, Flow Cytometry